Analysis of the C1-Esterase Inhibitor at patients with COVID-19 as a biomarker for the course of the disease
Recruiting
- Conditions
- COVID-19
- Registration Number
- DRKS00021440
- Lead Sponsor
- niversitätsklinikum Gießen und Marburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
positive PCR SARS-CoV-2; treatment on intensive care unit or home quarantine
Exclusion Criteria
age < 18 years
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentration and activity of C1-Esterase-Inhibitor.<br><br>Blood withdrawal is performed singular after informed consent with the morning routine.
- Secondary Outcome Measures
Name Time Method Concentration of des-Arg9-Bradykin<br>Concentration of Angiotensin II<br>Murray Score for ARDS<br>Acute Kidney Injurie<br>Dialysis<br>Arrhythmia<br>Troponin<br>CRP<br>PCT<br>Lymphocytes<br>GOT<br>GPT<br>LDH<br>D-Dimere<br>Fibrinogen<br>The above-mentioned parameters are registered at the timepoint of blood withdrawal.<br>The following parameters are captured after hospital discharge.<br><br>28 days lethality<br>duration of stay on intensive care <br>duration of stay at hospital<br>duration of ventilation